A Phase III Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi- centre, Multinational Study to Evaluate Efficacy and Safety of TRC150094 as an Add-On to Standard of Care in Improving Cardiovascular Risk in Subjects with Diabetes, Dyslipidemia and Hypertension